STAT3 and colorectal carcinoma: Through immunoblotting experiment, we found that the p-ERK and p-STAT3 was reduced during treatment of trametinib and fedratinib, respectively, indicating that the activity of MAPK pathway was disturbed through trametinib treatment in CRC organoids, and fedratinib may inhibit CRC growth by inhibiting the JAK/STAT pathway (Figs. 5F and S7).